These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31181267)

  • 1. Antibody therapeutics and immunoregulation in cancer and autoimmune disease.
    Yasunaga M
    Semin Cancer Biol; 2020 Aug; 64():1-12. PubMed ID: 31181267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease.
    Yasunaga M; Manabe S; Matsumura Y
    Sci Rep; 2017 Sep; 7(1):10735. PubMed ID: 28878234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.
    Lenk L; Baccelli I; Laqua A; Heymann J; Reimer C; Dietterle A; Winterberg D; Mary C; Corallo F; Taurelle J; Narbeburu E; Neyton S; Déramé M; Pengam S; Vogiatzi F; Bornhauser B; Bourquin JP; Raffel S; Dovhan V; Schüler T; Escherich G; den Boer ML; Boer JM; Wessels W; Peipp M; Alten J; Antić Ž; Bergmann AK; Schrappe M; Cario G; Brüggemann M; Poirier N; Schewe DM
    Blood; 2024 Jun; 143(26):2735-2748. PubMed ID: 38518105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are mimotope vaccines a good alternative to monoclonal antibodies?
    Pourjafar M; Samadi P; Khoshinani HM; Saidijam M
    Immunotherapy; 2019 Jun; 11(9):795-800. PubMed ID: 31094256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review.
    Kaifu T; Nakamura A
    Int Immunol; 2017 Jul; 29(7):319-325. PubMed ID: 28910969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibody-Based Drugs and Other Recombinant Proteins for Diagnostics and Therapy of Viral Infections, Autoimmune Diseases and Cancer].
    Kuprash DV; Garib FY; Nedospasov SA
    Mol Biol (Mosk); 2017; 51(6):883-885. PubMed ID: 29271953
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.
    Boyman O; Surh CD; Sprent J
    Expert Opin Biol Ther; 2006 Dec; 6(12):1323-31. PubMed ID: 17223740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor occupancy and blocking of STAT5 signaling by an anti-IL-7 receptor α antibody in cynomolgus monkeys.
    Kern B; Li W; Bono C; Lee LF; Kraynov E
    Cytometry B Clin Cytom; 2016 Mar; 90(2):191-8. PubMed ID: 25914284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
    Teige I; Mårtensson L; Frendéus BL
    Front Immunol; 2019; 10():481. PubMed ID: 30930905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
    Danlos FX; Voisin AL; Dyevre V; Michot JM; Routier E; Taillade L; Champiat S; Aspeslagh S; Haroche J; Albiges L; Massard C; Girard N; Dalle S; Besse B; Laghouati S; Soria JC; Mateus C; Robert C; Lanoy E; Marabelle A; Lambotte O
    Eur J Cancer; 2018 Mar; 91():21-29. PubMed ID: 29331748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease.
    Pantuck M; McDermott D; Drakaki A
    Cancer; 2019 Oct; 125(20):3506-3513. PubMed ID: 31318445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of immunotherapy in older adults: New treatments, new toxicities?
    Helissey C; Vicier C; Champiat S
    J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.